Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 3, 2012, Pages 189-197

  Habib, Shahid ^a   Boyer, Thomas D ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Ascites; Cirrhosis; Hepatorenal syndrome; Hyponatremia; Lixivaptan; Portal hypertension; Satavaptan; Tolvaptan; Vasopressin

Indexed keywords

ANGIOTENSIN; CONIVAPTAN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEMECLOCYCLINE; DIURETIC AGENT; LIXIVAPTAN; NORADRENALIN; PLACEBO; RELCOVAPTAN; RENIN; SATAVAPTAN; SODIUM; TOLVAPTAN; VASOPRESSIN;

ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOTENSIN BLOOD LEVEL; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; CARDIOPULMONARY INSUFFICIENCY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONSTIPATION; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS HEMORRHAGE; EXTRACELLULAR FLUID; FATIGUE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HEADACHE; HEART FAILURE; HEPATORENAL SYNDROME; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOVOLEMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INJECTION SITE REACTION; LIVER CIRRHOSIS; MORTALITY; NORADRENALIN BLOOD LEVEL; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SEPSIS; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THIRST; UREMIA; URINARY TRACT INFECTION; UROSEPSIS; VASOPRESSIN BLOOD LEVEL; WATER DEPRIVATION;

EID: 84860508849     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X12437357     Document Type: Review

References (22)

1. Angeli P. Wong F. Watson H. Ginès P. and CAPPS Investigators (2006) Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 44: 1535–1542.
2. Berl T. Quittnat-Pelletier F. Verbalis J.G. Schrier R.W. Bichet D.G. Ouyang J. et al. and SALTWATER Investigators (2010) Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21: 705–712.
3. Boyer T.D. (2010) Tolvaptan and hyponatremia in a patient with cirrhosis. Hepatology 51: 699–702.
4. Chung S.H. Jun D.W. Kim K.T. Chae J.D. Park E.K. Son B.K. et al. (2010) Aquaporin-2 urinary excretion in cirrhosis: relationship to vasopressin and nitric oxide. Dig Dis Sci 55: 1135–1141.
5. Gerbes A.L. Gülberg V. Ginès P. Decaux G. Gross P. Gandjini H. et al. and VPA Study Group (2003) Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 124: 933–939.
6. Ginès P. Berl T. Bernardi M. Bichet D.G. Hamon G. Jimenez W. et al. (1998) Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 8: 851–864.
7. Ginès P. Cardenas A. (2008) The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 28: 43–58.
8. Ginès P. Guevara M. (2008) Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 48: 1002–1010.
9. Ginès P. Wong F. Watson H. Milutinovic S. del Arbol L.R. Olteanu D. and Hypo CAT Study Investigators (2008) Effects of satavaptan, a selective vasopressin V (2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48: 204–213.
10. Ginès P. Wong F. Watson H. Terg R. Bruha R. Zarski J.P. et al. and Normo CAT Study Investigators (2010) Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V 2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 31: 834–845.
11. Hackworth W.A. Heuman D.M. Sanyal A.J. Fisher R.A. Sterling R.K. Luketic V.A. et al. (2009) Effect of hyponatraemia on outcomes following orthotopic liver transplantation. Liver Int 29: 1071–1077.
12. Kim W.R. Biggins S.W. Kremers W.K. Wiesner R.H. Kamath P.S. Benson J.T. et al. (2008) Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 359: 1018–1026.
13. Ku E. Nobakht N. Campese V.M. (2009) Lixivaptan: a novel vasopressin receptor antagonist. Expert Opin Investig Drugs 18: 657–662.
14. Kumar S. Berl T. (2008) Vasopressin antagonists in the treatment of water-retaining disorders. Semin Nephrol 28: 279–288.
15. Lemmens-Gruber R. Kamyar M. (2006) Vasopressin antagonists. Cell Mol Life Sci 63: 1766–1779.
16. Rozen-Zvi B. Yahav D. Gheorghiade M. Korzets A. Leibovici L. Gafter U. (2010) Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. Am J Kidney Dis 56: 325–337.
17. Schrier R.W. Arroyo V. Bernardi M. Epstein M. Henriksen J.M. Rodes J. (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151–1157.
18. Schrier R.W. Gross P. Gheorghiade M. Berl T. Verbalis J.G. Czerwiec F.S. et al. (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099–2112
19. Wong F. Blei A.T. Blendis L.M. Thuluvath P.J. (2003) A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37: 182–191.
20. Wong F. Ginès P. Nevens F. van Vlierberghe H. Gerbes A. Zarski J-P. et al. (2009) Double-blind placebo-controlled study of satavaptan in the management of recurrent ascites [abstract]. Hepatology 50(Suppl.): 448A.
21. Wong F. Ginès P. Watson H. Horsmans Y. Angeli P. Gow P. et al. (2010) Effects of a selective vasopressin V 2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 3: 283–290.
22. Wong F. Watson H. Gerbes A. Vilstrup H. Badalamenti S. Bernardi M. et al. and Satavaptan Investigators Group (2012) Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 61: 108–116.